Intraoperative Methylprednisolone and Neurodevelopmental Outcomes in Infants After Cardiac Surgery.

ABSTRACT:

Background

Neurodevelopmental impairment is an important consequence for survivors of surgery for critical congenital heart disease. This study sought to determine whether intraoperative methylprednisolone during neonatal cardiac surgery is associated with neurodevelopmental outcomes at 12 months of age and to identify early prognostic variables associated with neurodevelopmental outcomes.

Methods

We performed a planned secondary analysis of a 2-center, double-blind, randomized, placebo-controlled trial of intraoperative methylprednisolone in neonates undergoing cardiac surgery. A brain injury biomarker was measured during surgery. Bayley Scales of Infant and Toddler Development-III (BSID-III) were performed at 12 months of age. Two-sample t tests and generalized linear mode

SUBMITTER: Zyblewski SC 

PROVIDER: S-EPMC8514577 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature